Company intelligence / Profile preview
reMYND
Leuven, Flemish Region, Belgiumremynd.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Most advanced program for Alzheimer's treatment is in IND-enabling studies. Huntington's program has shown to fully restore cortico-striatal transmission and regenerate mouse brain in standard Huntington knock-in mice. Recent publication in Science highlighted neuroprotective qualities of septin modulation to restore calcium homeostasis.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Partnerships
Works with top pharmaceutical companies worldwide, including collaboration with Dr. Sugimoto (inventor of Aricept)
Beyond the preview
Go deeper on reMYND.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on reMYND.